HC Wainwright reissued their buy rating on shares of Repligen (NASDAQ:RGEN) in a report published on Monday morning, AnalystRatings.com reports. They currently have a $110.00 price objective on the biotechnology company’s stock.
“We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share.”,” HC Wainwright’s analyst commented.
Several other equities research analysts have also commented on RGEN. ValuEngine lowered shares of Repligen from a strong-buy rating to a buy rating in a report on Thursday, August 1st. Zacks Investment Research lowered shares of Repligen from a buy rating to a hold rating in a report on Wednesday, August 7th. Craig Hallum boosted their price target on shares of Repligen from $80.00 to $108.00 and gave the company a buy rating in a report on Monday, August 5th. Finally, BidaskClub upgraded shares of Repligen from a buy rating to a strong-buy rating in a report on Saturday, July 27th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and an average target price of $97.50.
NASDAQ:RGEN opened at $88.40 on Monday. Repligen has a one year low of $48.26 and a one year high of $99.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.88 and a current ratio of 2.25. The firm has a market cap of $4.56 billion, a P/E ratio of 121.10, a P/E/G ratio of 5.28 and a beta of 1.08. The firm has a 50-day simple moving average of $88.56 and a 200-day simple moving average of $70.26.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.25 by $0.06. Repligen had a net margin of 11.42% and a return on equity of 6.92%. The business had revenue of $70.70 million during the quarter, compared to analyst estimates of $65.47 million. During the same quarter in the previous year, the business posted $0.14 EPS. The company’s quarterly revenue was up 48.1% compared to the same quarter last year. On average, research analysts predict that Repligen will post 0.97 EPS for the current fiscal year.
In related news, Director Karen A. Dawes sold 1,295 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $77.35, for a total transaction of $100,168.25. Following the completion of the transaction, the director now owns 118,329 shares in the company, valued at approximately $9,152,748.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Glenn L. Md Cooper sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total transaction of $334,700.00. Following the transaction, the director now owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. BlackRock Inc. increased its stake in Repligen by 12.4% during the 2nd quarter. BlackRock Inc. now owns 6,350,552 shares of the biotechnology company’s stock valued at $545,830,000 after purchasing an additional 699,886 shares in the last quarter. Vanguard Group Inc. increased its stake in Repligen by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,420,485 shares of the biotechnology company’s stock valued at $379,940,000 after purchasing an additional 305,195 shares in the last quarter. Invesco Ltd. increased its stake in Repligen by 53.0% during the 2nd quarter. Invesco Ltd. now owns 3,088,594 shares of the biotechnology company’s stock valued at $265,465,000 after purchasing an additional 1,069,284 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Repligen by 3.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,698,329 shares of the biotechnology company’s stock valued at $145,971,000 after purchasing an additional 60,899 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its stake in Repligen by 9.0% during the 1st quarter. OppenheimerFunds Inc. now owns 1,082,943 shares of the biotechnology company’s stock valued at $63,980,000 after purchasing an additional 89,226 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.